{"url_path":"/sec/lnsr/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1320350/0001193125-26-214571-index.html","accession_number":"0001193125-26-214571","cik":"0001320350","ticker":"LNSR","issuer_name":"LENSAR, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1320350/0001193125-26-214571-index.html","primary_entity_key":"0001320350","primary_entity_name":"LENSAR, Inc."},"word_count":414,"has_tables":true,"body_markdown":"## Item 6. Exhibits\n\n \n\nExhibit\n\nNumber\n\nDescription\n\nForm\n\nFile No.\n\nExhibit\n\nFiling Date\n\nFiled/\n\nFurnished\n\nHerewith\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  2.1+\n\n[Separation and Distribution Agreement between PDL BioPharma, Inc. and LENSAR, Inc.](https://www.sec.gov/Archives/edgar/data/1320350/000119312520262511/d98252dex21.htm)\n\nForm 8-K\n\n001-39473\n\n2.1\n\n10/2/2020\n\n \n\n  3.1\n\n[Amended and Restated Certificate of Incorporation of LENSAR, Inc.](https://www.sec.gov/Archives/edgar/data/1320350/000119312520262511/d98252dex31.htm)\n\nForm 8-K\n\n001-39473\n\n3.1\n\n10/2/2020\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  3.2\n\n[Amended and Restated Bylaws of LENSAR, Inc.](https://www.sec.gov/Archives/edgar/data/1320350/000095017024123534/lnsr-ex3_2.htm)\n\nForm 10-Q\n\n001-39473\n\n3.2\n\n11/07/2024\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  3.3\n\n[Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock filed May 18, 2023](https://www.sec.gov/Archives/edgar/data/1320350/000119312523148214/d487803dex31.htm)\n\nForm 8-K\n\n001-39473\n\n3.1\n\n5/18/2023\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  4.1\n\n[Form of Certificate of Common Stock](https://www.sec.gov/Archives/edgar/data/1320350/000119312520245277/d945311dex41.htm)\n\nForm 10/A\n\n001-39473\n\n4.1\n\n9/14/2020\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  4.2\n\n[Registration Rights Agreement, dated May 12, 2023, between LENSAR, Inc, and NR-GRI Partners, LP](https://www.sec.gov/Archives/edgar/data/1320350/000119312523144213/d510326dex102.htm)\n\nForm 8-K\n\n001-39473\n\n10.2\n\n5/15/2023\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  4.3\n\n[Class A Common Stock Purchase Warrant, dated May 18, 2023](https://www.sec.gov/Archives/edgar/data/1320350/000119312523148214/d487803dex41.htm)\n\nForm 8-K\n\n001-39473\n\n4.1\n\n5/18/2023\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  4.4\n\n[Class B Common Stock Purchase Warrant, dated May 18, 2023](https://www.sec.gov/Archives/edgar/data/1320350/000119312523148214/d487803dex42.htm)\n\nForm 8-K\n\n001-39473\n\n4.2\n\n5/18/2023\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.1\n\n[Termination and Mutual Release Agreement, dated March 16, 2026, by and among Alcon Research LLC, VMI Option Merger Sub, Inc. and LENSAR, Inc.](https://www.sec.gov/Archives/edgar/data/1320350/000119312526109458/d27242dex101.htm)\n\nForm 8-K\n\n \n\n001-39473\n\n \n\n10.1\n\n \n\n3/17/2026\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n31.1\n\n[Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended](lnsr-ex31_1.htm)\n\n \n\n \n\n \n\n \n\n*\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n31.2\n\n[Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended](lnsr-ex31_2.htm)\n\n \n\n \n\n \n\n \n\n*\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n32.1\n\n[Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](lnsr-ex32_1.htm)\n\n \n\n \n\n \n\n \n\n**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n32.2\n\n[Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](lnsr-ex32_2.htm)\n\n \n\n \n\n \n\n \n\n**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.INS\n\nInline XBRL Instance Document - the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document\n\n \n\n \n\n \n\n \n\n*\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.SCH\n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n \n\n \n\n \n\n \n\n*\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n104\n\nCover Page Interactive Data File (as formatted as Inline XBRL and contained in Exhibit 101)\n\n \n\n \n\n \n\n \n\n*\n\n \n\n* Filed herewith.\n\n** Furnished herewith.\n\n74\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nLENSAR, Inc.\n\n \n\nDate: May 8, 2026\n\n \n\nBy:\n\n/s/ Nicholas T. Curtis\n\n \n\n \n\n \n\nNicholas T. Curtis\n\n \n\n \n\n \n\nChief Executive Officer\n\n \n\n \n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\n \n\nDate: May 8, 2026\n\n \n\n \n\n/s/ Thomas R. Staab, II\n\n \n\n \n\n \n\nThomas R. Staab, II\n\n \n\n \n\n \n\nChief Financial Officer\n\n \n\n \n\n \n\n(Principal Financial Officer)\n\n \n\n \n\n \n\n \n\nDate: May 8, 2026\n\n \n\n \n\n/s/ Kendra W. Wong\n\n \n\n \n\n \n\nKendra W. Wong\n\n \n\n \n\n \n\nPrincipal Accounting Officer\n\n \n\n \n\n \n\n(Principal Accounting Officer)\n\n \n\n75"}